#South Korea #Seoul #Nexsphere-F #Nexsphere #CIRSE

NEXTBIOMEDICAL's Remarkable Showcase at CIRSE 2026

NEXTBIOMEDICAL, a leading name in the medical device industry, recently marked a historical milestone at CIRSE 2026, held from September 5 to 9 in Copenhagen, Denmark. This annual congress of the Cardiovascular and Interventional Radiological Society of Europe is renowned for being one of the largest gatherings of professionals in the field of interventional radiology, boasting a rich 40-year history.

At this year's event, NEXTBIOMEDICAL significantly expanded its presence by hosting a large exhibition booth alongside a dedicated Learning Center. The Learning Center, which hosted sessions over three full days, featured insights from seven prominent Key Opinion Leaders (KOLs) from various countries, including the U.S., Germany, and Japan. Attendees were engaged in 11 sessions that covered the latest clinical and research developments in embolization techniques.

Showcasing Nexsphere and Nexsphere-F

The main highlights of NEXTBIOMEDICAL’s participation included its innovative embolic agents, Nexsphere™ and Nexsphere-F™, which garnered significant attention for their clinical applications. The sessions delved deep into various embolization procedures such as Musculoskeletal Embolization (MSKE), Genicular Artery Embolization (GAE), Uterine Artery Embolization (UAE), and Transarterial Chemoembolization (TACE). Physicians had the unique opportunity to engage in hands-on sessions with these products, allowing them to personally experience their potential in clinical settings.

Dr. Yuji Okuno, a well-respected figure in the embolization field, shared his extensive clinical experience using Nexsphere-F for different joint conditions. Over his career, Dr. Okuno has treated approximately 1,000 patients with Nexsphere-F, reporting a lack of serious adverse events. This showcases not just the safety profile but also the efficacy of the product as a primary embolic agent for arthritis treatment at the Okuno Clinic in Japan.

Meanwhile, Dr. Osman Ahmed from the Joint Vascular Institute presented his experiences with GAE in osteoarthritis patients, further solidifying the relevance and application of Nexsphere in contemporary medical practices. Additionally, other KOLs like Prof. Federico Collettini and Prof. Florian Fleckenstein shared compelling clinical cases that demonstrated how NEXTBIOMEDICAL's products enhanced treatment outcomes across diverse patient populations.

Broadening Market Presence

The dynamic discussions during CIRSE 2026 underscored NEXTBIOMEDICAL's ambition to expand its market footprint, particularly in the U.S. With in-depth discussions with global medical device companies aimed at forming strategic partnerships, the company is actively paving the way for Nexsphere-F's U.S. market entry. This strategy goes beyond mere distribution agreements; it involves forging partnerships with established entities that possess robust clinical networks and market experience in the musculoskeletal area.

A clinical trial is currently underway for Nexsphere-F, with approximately 80% of the targeted patient enrollment already completed. NEXTBIOMEDICAL is optimistic about successfully meeting its FDA approval goals, which will enable them to not only penetrate the U.S. market but also enhance their international growth.

Conclusion

CIRSE 2026 served as a pivotal platform for NEXTBIOMEDICAL to showcase its commitment to advancing therapeutic solutions in interventional radiology. With its innovative products, expanding clinical evidence, and a clear strategy for U.S. market entry, NEXTBIOMEDICAL is well-positioned to lead the industry in providing cutting-edge solutions that meet the evolving needs of healthcare professionals and their patients.